Boston Scientific Expects Synergy To Dominate Drug-Eluting Stents In US

Boston Scientific wants to expand the lead against other stents used by interventional cardiologists with the launch of its bioabsorbable Synergy drug-eluting stent. The company expects it will become the workhorse of the industry to handle a broad range of surgeries to treat coronary artery disease.